Welcome to our dedicated page for Zura Bio news (Ticker: ZURA), a resource for investors and traders seeking the latest updates and insights on Zura Bio stock.
Zura Bio Limited reports news on its clinical-stage immunology pipeline for autoimmune and inflammatory diseases. The company develops dual-pathway antibody candidates, led by tibulizumab (ZB-106), which targets IL-17A and BAFF and is being evaluated in Phase 2 studies for hidradenitis suppurativa and systemic sclerosis. Its additional clinical-stage candidates include crebankitug (ZB-168), targeting IL-7R, and torudokimab (ZB-880), targeting IL-33.
Recurring updates cover clinical study designs and presentations, financial results, corporate presentations, leadership and board changes, equity incentive grants, and capital-raising activity involving Class A ordinary shares and pre-funded warrants.
Zura Bio, a clinical-stage immunology company, announced its scheduled presentation at EULAR 2024 in Vienna from June 12-15. The company will unveil data on tibulizumab (ZB-106), a dual-pathway antibody targeting IL-17A and BAFF, focusing on its potential for treating Sjogren's syndrome and rheumatoid arthritis. The data aims to illustrate the antibody's capacity to inhibit both pathways in a single therapy, potentially broadening its clinical applications across various autoimmune diseases. Zura Bio also disclosed timelines for Phase 2 trials: systemic sclerosis in Q4 2024 and hidradenitis suppurativa in Q2 2025.
Zura Bio, a clinical-stage immunology company with a focus on novel dual-pathway antibodies for autoimmune and inflammatory diseases, announced participation in two June investor conferences. Chief Scientific Officer Michael Howell will attend one-on-one meetings at the Jefferies Global Healthcare Conference on June 6, 2024, in New York. CEO Robert Lisicki will participate in a panel discussion on dermatological disorders and hold one-on-one meetings at the Oppenheimer Novel Targets in Immunology Summit on June 24, 2024, in New York. These events aim to strengthen investor relations and provide insights into Zura Bio's innovative clinical programs.
Zura Bio reported financial results for Q1 2024, ending with $89.8M in cash and closing an oversubscribed $112.5M private placement in April. The company appointed a new CEO and CMO and is on track to start Phase 2 studies for SSc and HS. Cash runway extended through 2027. R&D expenses decreased, while G&A expenses increased. Net loss reduced. Anticipated milestones include Phase 2 trials for ZB-106 and monitoring of ZB-168 and ZB-880.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.